For the quarter ending 2025-09-30, RPTX had $5,169K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss for the period | 3,258 | -46,787 |
| Share-based compensation expense | 1,409 | 6,047 |
| Depreciation expense | 72 | 2,222 |
| Non-cash lease expense | 299 | 1,295 |
| Foreign exchange gain | -39 | 117 |
| Net accretion of marketable securities | 480 | 1,006 |
| Gain on sale of technology and other assets | 130 | 5,666 |
| Gain on termination of collaboration agreement | 3,257 | - |
| Impairment loss on rou asset | 330 | - |
| Prepaid expenses | 1,052 | -3,006 |
| Other current receivables | -1,463 | -67 |
| Other non-current assets | 0 | -179 |
| Deferred collaboration cost recovery | - | 3,257 |
| Accounts payable | -2,667 | 382 |
| Accrued expenses and other current liabilities | -2,223 | -7,652 |
| Operating lease liability, current portion | -302 | -1,223 |
| Income taxes | 9,149 | 609 |
| Operating lease liability, net of current portion | 0 | -88 |
| Deferred revenue | 0 | 0 |
| Net cash used in operating activities | 2,651 | -45,475 |
| Proceeds from sale of technology and other assets | 0 | 1,000 |
| Proceeds from maturities of marketable securities | 10,150 | 73,662 |
| Purchase of marketable securities | 7,613 | 46,456 |
| Net cash provided by investing activities | 2,537 | 28,206 |
| Proceeds from exercise of stock options | 0 | 0 |
| Proceeds from issuance of common stock under the 2020 employee share purchase plan | 30 | 79 |
| Net cash provided by financing activities | 30 | 79 |
| Effect of exchange rate fluctuations on cash held | -49 | 129 |
| Net decrease in cash and cash equivalents | 5,169 | -17,061 |
| Cash and cash equivalents at beginning of period | 84,717 | - |
| Cash and cash equivalents at end of period | 72,825 | - |
Repare Therapeutics Inc. (RPTX)
Repare Therapeutics Inc. (RPTX)